Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Abstract | BACKGROUND: METHODS: RESULTS: Sixty-four of 66 patients were analyzed. After chemotherapy and RT, 61 patients had surgery; 58 had R0 resections (5 amputations), and 3 had R1 resections. Ninety-seven percent experienced grade 3 or higher toxicity, including 3 deaths. These toxicities were short term. With a median follow-up of 7.7 years in surviving patients, the 5-year rates of locoregional failure (including amputation), and distant metastasis were 22.2% (95% confidence interval [CI], 11.8-32.6) and 28.1% (95% CI, 17.0-39.2). The most common site of metastasis was lung. Estimated 5-year rates of disease-free survival, distant disease-free survival, and overall survival were 56.1% (95% CI, 43.9-68.3), 64.1% (95% CI, 52.3-75.8), and 71.2% (95% CI, 60.0-82.5), respectively. CONCLUSIONS: Although the toxicity was significant, it was limited in its course and for the most part resolved by 1 year. The long-term outcome was better than might be expected in such high-risk tumors.
|
Authors | William G Kraybill, Jonathan Harris, Ira J Spiro, David S Ettinger, Thomas F DeLaney, Ronald H Blum, David R Lucas, David C Harmon, G Douglas Letson, Burton Eisenberg |
Journal | Cancer
(Cancer)
Vol. 116
Issue 19
Pg. 4613-21
(Oct 01 2010)
ISSN: 0008-543X [Print] United States |
PMID | 20572040
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2010 American Cancer Society. |
Topics |
- Abdominal Wall
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Extremities
- Humans
- Neoadjuvant Therapy
- Radiotherapy, Adjuvant
- Risk
- Soft Tissue Neoplasms
(drug therapy, pathology, radiotherapy)
- Thoracic Wall
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|